Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I also remember your good analysis and insight on Leronlimab.
But I also remember how you shielded any criticism of Nader for a very long time. Even after the big Dr. Pestell blunder which cost us north of 20million shares and precious time in the cancer trials. Nader awarded himself millions of shares for this donkey, you did not allow any criticism on Nader. Although later the narrative changed then to "too late to change the CEO at this stage".
Nader was your blind spot for far too long in this investment, but you realized soon enough and pulled the trigger. Congratulations!
Unfortunately I was not so foresighted like you and sticked with the investment to 100%, because I still believe on the success of Leronlimab.
I hope you are doing well!
Have you asked/ emailed Scott Kelly about this?
Just do not ask Nader about this matter.You might get an an answer like "The FDA is in our favor and give us guidance, they are just great to us and the support us in all possible ways!!!"
Does anybody know if OLE and EIND for Leronlimab is already stopped by now?
Is there a webpage where one can check the status?
Can someone explain to me how this numbers add up?
Nader stated that our trial had 87 dead patients near the trial finish line.
Based on the knowledge that usually 30% of patients died in the placebo arm at other similar COVID trials, some folks calculated that the overall reduction of mortality at CD12 should be somewhere around 40%.
Now we know that we have "only" a 24% mortality reduction at the critical patients population.
following possibilities:
1. Nader told us nonsense with the 87 patients or this number was misleading.
2. We had unusual healthy patients at the placebo arm (mortality lower than 30%)
3.This means we should have mind blowing results at the severe patient population, to "reach" the calculated 40% reduction of the whole CD12 trial.
Which is it?
It does not make any sense to me either.
At the moment I am thinking this was another bad worded PR from Nader/ Kelly.
Maybe Nader can achieve a similar contract/ deal with J&J as we have done for HIV with Vyera Pharmaceuticals LLC? Hopefully with better conditions.
A license for COVID alone would generate billions of revenue for CYDY in the coming years. Think about what other trial we can start with a few billions a year and at what speed.
CYDY marketcap could go exponential in the coming years.
Why is here nobody talking about the changed rules in the Philippines?
https://www.fda.gov.ph/clarification-on-the-issuance-of-emergency-use-authorization-eua-from-the-national-task-force-against-covid-19/
How can it be that the Longhauler trial did not start yet?
When did they send the modification for the trial to the FDA? Mid of January?
What is the FDA waiting for?
Börse Stuttgart: 5.85EUR = 7.07USD
realtime data (only a few sec. delayed):
https://www.boerse-stuttgart.de/de-de/produkte/aktien/stuttgart/a0yha5-cytodyn-inc------dl--01/times-and-sales
blue horseshoe loves CYTODYN
As other already suspect, they are probably well funded and backed by BP.
Nobody is that insane to have currently well above 28,5M shares short (at current shareprice this is more than 134MUSD) without an insurance policy.
New short numbers are out:https://otce.finra.org/otce/equityShortInterest
On 31.12.2020 there were 28,551,479 shares sold short, this is an increase of 1,507,973 shares.
I guess so far this number even increased in January!
I am also feed up with the empty talk (the list is pretty impressive) of Nader over the last three years, but I think the NASDAQ listing is for real and can be accomplished within a few days/ weeks.
Even a blind hen sometimes finds a grain of corn and Nader is picking for a very long time :)
In my understanding they have done 98% of the work for the uplisting and they have a clear picture what to do. It is just a matter of clearing the few remaining roadblocks. Once this is done, they more or less have to send the application to NASDAQ and wait.
This is the damn job of the CFO and not one of the many duties of Nader or Kelly. So why should they delay the uplisting and wait for revenue?
They make all the work for a NASDAQ uplisting and then thy decide to do dump it and start the listing process for NYSE? Does not make any sense to me.
Do not forget the possibility of a NASDAQ Listing which could be announced any minute.
I assume Nader and Kelly are currently working to get all ducks in a row to finally orchestrate the epic beating the shortys deserve for some time now.
They just have to convert some debts into shares and we have checked all important check boxes for a NASDAQ listing.
This could result in an epic shortsqueez if you combine this with the optimal timing of the CD-12 TLD.
This is it!
The most constant positive for shareholders from those CCs is the possibility to add shares on the cheap the next day.
Damn it, I expected the short seller to do a better job!
Hit it baby one more time! :)
I am a little bit disappointed about the shorts. Is this all they have?
I expected sub 4.9USD to load up the boat for the last time.
Come on, dump whatever you have left!
My expectations for todays call:
Description of an epic shortsqueeeez:
1. All shareholder put a sell order of max. 1% of their total shares at 400USD.
2. The company announces an uplisting to NASDAQ.
3. All shareholders do not sell any shares for three days below 400USD.
The shortsqueez of Volkswage, a few years back, would look like a walk in the partk for the shortsellers.
=> everybody wins and the world would be freed from a few shortsellers less :)
Does anybody know when the next update regarding shorts will be available?
According to this page https://fintel.io/ss/us/cydy it looks like it is updated approx. every 15 days, so we are overdue for a new short number.
Does anybody know if the four patients in the Agresti paper were selected randomly within a certain timeframe or were they carefully selected?
I am just curious if he just had a lucky hand and selected four patients which reacted very well on Leronlimab.
Estimated Study Start Date : December 21, 2020
Estimated Primary Completion Date : March 23, 2021
Estimated Study Completion Date : March 23, 2021
I guess the 91 weeks are only "follow up"
Can you please elaborate on
No worries, Joshua Gold seems to be on the scammers backburner and so a pump seems not to be imminent.
They are now gobbling up all shares at SRSR which means they are preparing themselves for the next big scam there.
ok, after a second check it quite explicitly says
After a quick search I cannot find this requirement (EUA in country of origin) on the webpage of the FDA Philippines.
https://www.fda.gov.ph/category/circular/
I assume they would mention such an important and fundamental requirement on their own webpage!
This is what the FDA announced as condition for EUA:
Only a few weeks (trading days) left until TLD from the CD12 trial is expected.
It will be great to watch how FOMO investors and shortsellers will fight for every single share at some point in the coming weeks. I will grab my popcorn and will watch how the shorts will try to cover and get burned heavily in the process.
I think it will be like a rollercoaster ride until end of January, but the real fun starts in February and the following months.
Exciting weeks ahead!
Is the triple negative breast cancer study running again? I can remember they did not enroll new patients for some time, since they changed the protocol for 700mg injections(?)
The clinicaltrials.gov page is not always up to date.
Does anybody know the actual status?
I hope we get an update on Dr. Mahboob relationship with his son.
Man this was at least entertaining :)
Where does it say only 290 patients in the UK?
add F.1.2.1(300) and F.1.3.1 (90) and you get 390 patients.
the same with F.4.2.1 and F.4.2.2 => 390 patients
Retrospectively it was a big mistake not to push CD12 from the beginning like they do now for the last few weeks.
The mortality rate has improved since the first wave, so I guess our chances of very good data did not improve over time.
I guess this is due to the learning curve of Nader and Kelly.
I still believe our data will be very good, but I am not sure good enough for FDA.
Nader and Kelly do not realize that FDA plays the same game they are playing with us at HIV. FDA is buying time for their BP buddies.
What is the problem for just simply ask for EUA? How can this be negative in any way for Cytodyn?
Will he also politely ask FDA if he can file EUA for CD12 too? If they tell him to get lost on the phone, what will he do? Will he finally start fighting back?
This is madness.
I guess they are trying to figure out how to pump this filthy donkey one more time. They are loaded with worthless stocks which they gave themselves over the years, and they cannot unload. What a tragedy :)
I think we should go to Africa to make some trials, when they get hit by the next Ebola epidemic. Big pharma is not really interested in a "poor country" deseas which earn them not big bucks. Recruiting should be easy and they have nothing to lose.
USA and Europe are rotten by corruption in the agencies and media. We are lost ...
Are thee any news regarding Chris Christi? With his asthma and his other health issues it seems he would be a very good trial patient for Leronlimab
So if somebody has a question regarding the drill holes, they call you for more information? Are you working for the company or are you just an undisclosed insider?
With this kind of people at the companies helm and certain people surrounding the company, the drill hole could show pure gold over the whole length and still nobody would touch this dog with fleas.
I am still waiting to see Bend Ward and Scott Keevil joining the management team at some point. lol
Germany is and was never an indicator for the OTC opening. Until now there were only 3126 shares traded in Stuttgart today, which is nothing. The spread between Bid and Ask tells a similar story => Germany is not price relevant.